Atara Biotherapeutics, Inc.: updates and filings

ATRANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.50

November 17, 2026Market cap $100M

What Ploutos Investor adds for Atara Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 16, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 10, 2026Shelf registration for future offerings
    FormS-3
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 12, 2026Results of operations
    Form8-K
  • Jul 24, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 26, 2026Officer or director change
    Form8-K
  • Jun 12, 2026Shares registered for employees
    FormS-8
  • Jun 12, 2026Officer or director change, shareholder vote
    Form8-K
  • May 14, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Financial statements and exhibits
    Form8-K
  • May 11, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 8, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 7, 2026Other material events
    Form8-K
  • May 1, 2026Delisting notice
    Form8-K
  • Apr 24, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 24, 2026Additional annual meeting material
    FormDEFA14A
  • Mar 25, 2026Filing
    FormEFFECT
  • Mar 23, 2026Correspondence with the SEC
    FormCORRESP
  • Mar 20, 2026Letter from the SEC
    FormUPLOAD
  • Mar 17, 2026Shelf registration for future offerings
    FormS-3

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 10, 2014.

The full analysis

What do Atara Biotherapeutics's filings show?

The filings are where every one of Atara Biotherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.